KIMS Hospitals partners with UAIMS Hospital in Sangli

Published On 2025-02-18 09:22 GMT   |   Update On 2025-02-18 09:22 GMT

KIMS Partners with UAIMS Hospital in Sangali 

Karad: Krishna Institute of Medical Sciences Ltd (KIMS) has announced an operations and management agreement with Ushahkal Abhinav Institute of Medical Sciences (UAIMS Hospital) in Sangli, Maharashtra, as part of its strategy to expand its healthcare presence.

The agreement, signed on February 17, 2025, spans an initial period of seven years, with an option to extend for an additional three years. Under the terms of the agreement, KIMS will have exclusive rights to provide medical services for both current and future operations of the hospital.

UAIMS, a state-of-the-art quaternary care facility, was founded in 2022 and boasts a capacity of 316 beds, with plans for future expansion to over 500 beds. The hospital is equipped with cutting-edge medical technology, including CT and MRI machines, 15 advanced operation theatres, and a dedicated mother and child care facility. The facility spans four acres, offering one of the highest floor-area-to-bed ratios in the region, and focuses heavily on critical care, providing more than 100 critical care beds with advanced medical infrastructure.

Also Read: KIMS acquires 100 per cent stake in 200-bed 'Queen's NRI Hospital' in Andhra Pradesh

According to Cnbctv18, UAIMS has also announced the launch of a comprehensive daycare oncology center adjacent to the hospital. This facility is currently under construction and is expected to be operationalized in 2025. KIMS will oversee the hospital’s full management, operations, and service delivery under the KIMS-UAIMS brand.

As part of the agreement, KIMS will receive 9% of the hospital’s net revenue. The partnership also includes a First Right of Refusal (ROFR) for KIMS and its affiliates to acquire profit-sharing from existing partners during the contract period. Additionally, KIMS has the option to acquire a majority profit share in UAIMS at its discretion.

KIMS has been actively expanding its presence in Maharashtra. In 2022, the company acquired Kingsway Hospital in Nagpur, followed by the launch of a second hospital in Nashik in 2024. KIMS is also planning to open a 300-bed multi-specialty hospital in Thane, scheduled to begin operations in the first quarter of the upcoming financial year.

Also Read: KIMS Hospital unveils state-of-the-art stroke centre

Speaking to Cnbctv18, Dr Bhaskar Rao, Chairman and Managing Director, said, "Maharashtra is an important market for us. Our foray into Sangli signifies our commitment to bring our trusted affordable, advanced, and accessible healthcare model to more geographies of Maharashtra. We will continue to look for a mix of greenfield and brownfield strategies for ramping up our presence in Maharashtra."

According to the news reports, despite the positive strategic developments, KIMS' stock saw a decline of 3.85%, closing at ₹558.70 on the Bombay Stock Exchange (BSE) on February 17, 2025.

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News